



SAGE Therapeutics, Inc.
Investor Relations Department
215 First Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: SAGE

Last Trade:	62.90
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	-2.09 (-3.216%)
Day Range	62.70 - 65.48
52-Week Range	38.30 - 90.80
Volume	566,946

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 22, 2017
[Sage Therapeutics to Participate in Leerink Investor Conference](#)
- Sep 12, 2017
[Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus](#)
- Sep 7, 2017
[Sage Therapeutics to Present at Morgan Stanley Healthcare Conference](#)
- Sep 6, 2017
[Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Aug 3, 2017
[Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update](#)

Upcoming Events [\[View all \]](#)

- Sep 27, 2017 2:00 PM ET
[Leerink Partners Rare Disease Roundtable](#)
- Financials [\[View all \]](#)
[First Quarter Financial Results](#)
- Feb 24, 2017
[Annual Report \(10-K\)](#)
- Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017
[Quarterly Report \(10-Q\)](#)
- May 10, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016
[Quarterly Report \(10-Q\)](#)